Compare IFF & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFF | DGX |
|---|---|---|
| Founded | 1833 | 1967 |
| Country | United States | United States |
| Employees | N/A | 57000 |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 21.0B |
| IPO Year | 2010 | 1996 |
| Metric | IFF | DGX |
|---|---|---|
| Price | $74.64 | $193.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $89.09 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 1.6M | 763.5K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | ★ 2.32% | 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | 0.66 | ★ 2.24 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | N/A | $7.53 |
| Revenue Next Year | $3.11 | $3.77 |
| P/E Ratio | $112.76 | ★ $86.51 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $59.14 | $164.65 |
| 52 Week High | $84.45 | $213.50 |
| Indicator | IFF | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 52.69 |
| Support Level | $67.44 | $192.76 |
| Resistance Level | $75.32 | $200.49 |
| Average True Range (ATR) | 2.73 | 3.85 |
| MACD | -0.33 | 0.30 |
| Stochastic Oscillator | 33.79 | 75.37 |
International Flavors & Fragrances is the largest specialty ingredients producer globally. It sells ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations, partnering with customers to deliver custom solutions. Through its taste and scent segments, which each generate around 25% of profits, IFF is a leading flavor and fragrances producer. The health and biosciences business, which generates 30% of profits, is a global leader in probiotics and enzymes. The remaining profits come from the food ingredients business, which sells texturants, plant-based proteins, and other ingredients, though IFF plans to divest this business in the future.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.